No cases of COVID-19 were observed after two doses of the vaccine using the primary case definition, consistent with a vaccine efficacy of 100%.

The TeenCove study also showed a vaccine efficacy of 93% using the secondary U.S. Centers for Disease Control and Prevention (CDC) case definition of COVID-19, which tested for milder disease.

All participants will be monitored for one year after their second injection to assess long-term protection and safety, Moderna said.

The firm plans to submit the data to regulators globally early next month and request authorization for the vaccine for teens.

Moderna inks South Korean mRNA vaccine collaborations
Moderna has inked two memoranda of understanding agreements with South Korea for messenger RNA (mRNA) vaccine research and manufacturing in that country.

Japan approves Moderna COVID-19 vaccine
Japan's Ministry of Health, Labour, and Welfare recently approved Moderna's COVID-19 vaccine, and distribution in the country by Takeda will begin immediately.

Moderna booster produces antibodies against SARS-CoV-2 variants
Moderna announced that initial results from a phase II study suggest a single booster dose of its messenger RNA (mRNA) vaccine candidates mRNA-1273 or...

Moderna increases manufacturing capacity
Moderna has doubled the size of its manufacturing technology center in Norwood, MA, expanding the facility from a production and lab space into an industrial...

Moderna secures WHO emergency use listing for COVID-19 vaccine
Moderna has secured emergency use listing from the World Health Organization (WHO) for its COVID-19 vaccine.